Araclon Begins Phase 2 Trial of Vaccine for Alzheimer’s Disease

Araclon Begins Phase 2 Trial of Vaccine for Alzheimer’s Disease
Araclon Biotech is launching a Phase 2 clinical trial evaluating its active immunotherapy, or vaccine, ABvac40 for Alzheimer’s disease, after receiving approval from the Spanish Agency of Medicinal Products and Medical Devices. The multi-center trial will include 22 European clinical facilities (18 centers in Spain, two in France, one in Sweden and one in Italy). A total of 120 patients are estimated to be enrolled in the two-year trial, designed to confirm safety and tolerability data obtained in Phase 1 clinical studies of ABvac40 and to establish a dose regimen for the therapy. Of the 120 participants, some will not yet have developed symptoms of dementia — called prodromal patie
Subscribe or to access all post and page content.

2 comments

  1. kourosh says:

    Great job!
    I hope the Vaccine stop the progression of disease in patients who are already suffering from mild dementia.

  2. Doogie Howser says:

    we need a global commitment of the people to force the health community and Big Pharma along with their sponsored politicians to release those who are making improvements, than continuing to allow doctors to deny the disease any real rememdies.

Leave a Comment

Your email address will not be published. Required fields are marked *